Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

ReportsWorldwide has announced the addition of a new report title
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects to its growing collection of premium market research reports.

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.

Scope of the Report:

The escalating T2DM public healthcare need has resulted in a competitive market landscape

- What is the pathophysiology of T2DM?

- What are the common co-morbidities and complications?

- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?

- What are the most significant unmet needs within the market?
The T2DM pipeline is large and innovative

- Which molecule types and molecular targets are most prominent within the pipeline?

- Which first-in-class targets are most promising?

- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The T2DM deals landscape is highly active

- Do T2DM products attract high deal values?

- Which molecule types and molecular targets dominate the deals landscape?

- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6856

Reasons to buy

This report will allow you to -

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.

- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.

- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/frontier-pharma-type-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline-with-most-promising-first-in-class-targets-demonstrating-potential-disease-modifying-effects

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.